To date, unmodified RNA-aptamers have been selected against the purified extracellular domain of EGFR and then used for gold-nanoparticles delivery to cancer cells [18] or, in a surface-immobilized form, to capture EGFR-expressing glioma cells [19]. This evidence concerns the gene EGFR and central nervous system cancer.